Developing new drug products is very expensive, especially
|
|
- Elmer Wheeler
- 5 years ago
- Views:
Transcription
1 As appeared in March 2018 Tablets & Capsules formulation Developing fixed-dose combinations Amar Patel, Bruhalkumar Shah, Deep Patel, Satish Shetty, and Anthony Qu Halo Pharmaceuticals Fixed-dose combination (FDC) drug products are a safe and cost-effective way for pharmaceutical companies to extend patent protections and improve patient adherence to drug therapy, but developing FDCs can be challenging. This article discusses FDC development and the importance of using a quality-by-design approach when developing an FDC. Developing new drug products is very expensive, especially when formulating new chemical entities (NCEs). Many pharmaceutical companies are turning to FDCs as a way to reduce those development costs. An FDC is a drug product that combines two or more active pharmaceutical ingredients (APIs or drugs) in a single dosage form. FDCs are acceptable only when the dosage of each API meets the
2 Photo 1: The granular or powder material making up the two layers in a bilayer tablet should have similar physical properties, including particle size distribution, bulk density, and flow characteristics. requirements of a defined population group and when the combination has a proven advantage over single compounds administered separately in therapeutic effect, safety, or compliance. FDCs provide greater convenience and can increase patient compliance because they require patients to take fewer doses [1]. FDCs can be particularly beneficial when used to treat life-threatening diseases such as HIV/AIDS, diabetes, or cardiovascular disease, where a single drug targeting a specific receptor is not considered optimal. For instance, in the case of cardiovascular disease, a combination of antihypertensive and antihyperlipidemic drugs is more beneficial for patients than taking the individual drugs separately because it reduces multiple risk factors without increasing the risk of adverse effects [2]. Similarly, in the case of HIV, an FDC prevents viral drug resistance by decreasing the level of viral replication and raising the barrier to resistance development [3]. An FDC can also improve an API s bioavailability by combining the API with a drug-metabolizing enzyme inhibitor. Aside from the approval status of the APIs to be combined, the primary consideration when developing an FDC is the development strategy. The FDA has encouraged FDC development, as evidenced by the number of FDC products the agency has approved. From 1990 through 2013, the FDA approved 131 FDC products (an average of 5.7 per year). The largest number of these targeted indications related to cardiovascular disease, followed by endocrinology and infectious diseases. Of the 131 approved FDCs, 98 were oral dosage forms. Between 2010 and the end of 2015, 63 of the 655 new drug applications (NDAs) approved by the FDA were for FDCs [4]. This represents nearly 10 percent of the NDAs approved during that 5-year period an average of 12.6 new FDC products per year. Photo 2: Mini-tablets have a diameter smaller than 3 millimeters and are manufactured using a conventional tablet press with specialized multi-tip tooling. Pharmaceutical manufacturers are developing and introducing more FDC s into the market because these drug products offer a promising strategy to repurpose, repackage, and expand indications for existing and novel therapeutic agents. Reformulating and combining approved drugs that are proven to be safe and effective into an FDC allows a company to extend and maintain patents or increase market share, which are potent financial incentives. Development considerations Aside from the approval status of the APIs to be combined, the primary consideration when developing an FDC is the development strategy. Companies typically select APIs for FDC development based on clinical experience and manufacturing feasibility along with the pharmacological mechanisms, biopharmaceutical properties, metabolic pathways, pharmacokinetics, drug-drug interactions, and required doses of the individual APIs [5]. The APIs to be combined should: act by different mechanisms; have similar pharmacokinetics; treat closely related diseases (such as hypertension and hyperlipidemia) or the same disease using different mechanisms (such as antidiuretics and angiotensin converting enzyme inhibitors); have minimal drug-drug interaction. An FDC formulation and development program typically involves a pilot-stage program followed by bioequivalence (BE) studies, which compare the FDC to the constituent drugs co-administered as individual entities. Food-effect bioavailability studies are also required to register the drug product with the FDA. The regulatory requirements may be particularly challenging for FDCs that combine two NCEs. Developing a good strategy and designing appropriate trials to evaluate the formulations, drug-drug interactions, and bioavailability are critical to ensure that the FDC will be stable,
3 Photo 3: The mini-tablet s small size allows developers to encapsulate multiple mini-tablets into a single FDC capsule. effective, and safe and that it will contain the optimal drug ratios as determined by dose-ranging studies. Solid dosage forms The solid dosage form of an FDC may be a monolayer tablet, a bilayer tablet, or a multi-particulate/mini-tablet system depending on the release profiles and chemical and physical compatibility of the APIs as well as clinical and dosing requirements. Monolayer tablets. A monolayer tablet is similar to a single-entity tablet except that it contains two or more APIs. To be processed together into a monolayer tablet, the APIs must be physically and chemically compatible with each other, and the dose of each API should not be too high. Additionally, the APIs should have similar dissolution profiles to ensure that the FDC can achieve bioequivalence to each single-entity drug product [6]. Bilayer tablets. A bilayer tablet (Photo 1), is similar to a conventional single-layer tablet but with two separate formulations pressed together. By separating incompatible components, a bilayer tablet formulation can significantly improve an FDC s overall chemical stability. In addition, a bilayer tablet is a convenient way to combine an immediate-release dose and a sustainedrelease dose of either the same drug or different drugs. To avoid potential formulation challenges such as inadequate compression or content uniformity, the granular or powder materials that comprise the two tablet layers should have similar physical properties, including particle size distribution, bulk density, and flow characteristics. It s also good practice to maintain a weight ratio between the two layers of not more than 6 to 1. Furthermore, if high drug loading (500 to 600 milligrams) is required in one layer to achieve pharmacological action, or if the weight of one layer must be kept high (800 to 1,200 milligrams) for formulation reasons, it s important to keep the overall tablet weight low enough (1,000 to 1,500 milligrams) for patient compliance. If maintaining a similar weight or composition between the layers isn t possible due to formulation requirements, then the particle size distribution of all the APIs and excipients should be uniform to prevent segregation and provide good flow and content uniformity. Multiparticulate/mini-tablet dosage forms. Multiparticulate or mini-tablet dosage forms are also useful for combining incompatible APIs or excipients or when a formulation requires that the APIs have different release profiles. The most commonly used multiparticulate oral solid dosage form is pelleted and/or powdered material compressed into a tablet or encapsulated into a capsule. A more recent manufacturing trend is to create various mini-tablets with diameters smaller than 3 millimeters (Photo 2), which can then be encapsulated into capsules (Photo 3) depending on the formulation s requirements. One of the most common technologies used to create pellets for a multiparticulate FDC is extrusionspheronization, where the formulation is granulated to prepare a wet mass, which is extruded into cylindrically shaped extrudates. The extrudates are then broken into smaller particles and rounded off to create spheres, which are then dried. Extrusion-spheronization allows for high drug loading and can create pellets with a narrow particle size distribution. The pellets are also durable, making them suitable for film coating for pulsatile drug delivery and combining immediate-release pellets with controlledrelease pellets of the same or a different drug. Adjusting the fill weight of the pellets into the capsule allows for dosing flexibility. Another way of producing a multiparticulate system is by preparing the drug in a solution or suspension and coating it onto readily available sugar pellets. You can then add an additional controlled-release coating to the pellets if required or combine immediate- and extendedrelease pellets. Development challenges and limitations Because FDCs contain more than one API, they re more challenging to develop than single-entity drug products. The challenges are largely related to formulation, dose-ranging, drug-drug interactions, and manufacturing processes. FDC development is also challenging when the APIs durations of action differ significantly. In some cases, drug interaction at the level of pharmacokinetics, efficacy, or safety may limit formulation potential. In other cases, the API dosage becomes too large to administer as a single form. Also, the potential for BE failure is a factor, particularly when the dissolution profiles of the APIs to be combined differ. FDC use may also be limited where the component therapies require dose titration or various dose adjustment patterns because it s not possible to alter the dosage of one drug in the FDC without altering the dosage of the other drug or drugs [7].
4 A dose differential between the APIs also poses formulation and processing challenges. For instance, if the dose of one API is low and the dose of the other API is high, each API should be processed individually and combined at the final stage as a bilayer, tablet-in-tablet, or capsule-in-capsule form. An FDC with three APIs, where API A and API B are low-dose and API C is high-dose with an extendedrelease profile, presents many formulation challenges. In such a case, you can formulate API A and API B using high-shear granulation and process the high-dose API C by extrusion spheronization technology. Then you can apply an extended-release polymer coating only to the API C spheres and compress the blended API A and API B granules and the coated API C spheres into a bilayer tablet. Other challenges associated with FDCs include: Drugs with differing pharmacokinetics create a problem of administration frequency when combined into an FDC. FDCs can increase the chances of adverse drug effects and drug interactions compared to single-api dosage forms. Determining the cause of an adverse drug reaction can be difficult because the FDC contains more than one API. Pharmacists and physicians may overlook the dosage limit of certain APIs in FDCs. Quality by design A quality-by-design (QbD) approach is critical when developing an FDC dosage form to meet the FDA s requirement for a robust formulation and manufacturing process. Although the application of QbD will be similar to the application for a single-api formulation, it will be more complex due to the presence of multiple APIs. The first and most important step is to define the target product profile (TPP), which describes the use, safety, and efficacy of the product. An in-depth understanding of formulation, excipients, and process is advantageous when defining the TPP and will reduce the amount of experimentation and analytical testing required and, consequently, the manufacturing and testing costs. The next step is to design the formulation and identify the critical quality attributes (CQA) of the final product that must be controlled to meet the TPP. To achieve the final product s critical quality attributes, it s important to identify and control critical process parameters (CPP). Throughout development, scale-up, and commercialization, establish a control strategy that includes rawmaterial and API controls (for particle size distribution, moisture, polymorphs, and impurities, among other characteristics), process controls (such as hardness, thickness, friability, tablet weight during compression, inlet temperature, spray rate, and exhaust temperature during tablet coating), and design space around individual or multiple unit operations (such as granulation, compression, coating, encapsulation, and packaging). It s equally important to monitor these controls and update the process to ensure target product profile. To achieve successful target product profile by QbD approach, it is important to use design of experiment (DOE), risk assessment, and process analytical technology (PAT). A QbD approach provides several advantages, including: negligible chance of batch failure because the batches are manufactured in a design space defined during product development; enhanced understanding of the formulation and manufacturing processes; the development of a robust process that leads to greater regulatory confidence; continuous improvement in the manufacturing process during development, validation, and postcommercialization in a defined design space doesn t require resubmission to the FDA; increased product quality, improved yields, reduced investigations and testing, and lower manufacturing costs; guaranteed therapeutic equivalence of each batch of generics manufactured; a better, less expensive, and safer drug product. By using a QbD approach, pharmaceutical companies can develop safe and effective FDCs that optimize the pharmacokinetics, bioavailability, and therapeutic effect of existing approved drug products. This benefits patients, particularly those on long-term management therapies, by reducing the administration burden and improving compliance. this also benefits pharmaceutical companies by extending patents, reducing manufacturing costs compared to single-api drug products, and shortening regulatory approval time and expense compared to NCE development. T&C References 1. Divyakant Desai, Jennifer Wang, Hong Wen, Xuhong Li, and Peter Timmins, Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms, Pharmaceutical Development and Technology, Vol. 18, No. 6, pages 1,265-1, Nazaneen Pourkavoos, Unique risks, benefits, and challenges of developing drug-drug combination products in a pharmaceutical industrial setting, Combination Products in Therapy, Vol. 2, No US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), Guidance for Industry: Fixed Dose Combinations, Co-Packaged Drug Products, and Single-Entity Versions of Previously Approved Antiretrovirals for the Treatment of HIV, Available at 4. Kyu Chan Kwon and Chulung Lee, Analysis of Fixed-Dose Combination Products Approved by the US
5 Food and Drug Administration, : Implications for Designing a Regulatory Shortcut to New Drug Application. Therapeutic Innovation & Regulatory Science, Vol. 51, No. 1, pages Jagannath Kota, Phaninatha Sarma Ayalavajjala, and Rama Sivasubramanian, Development of orally administered fixed dose combination (FDC) products: Pharmacokinetic and biopharmaceutical considerations, International Journal of Pharmaceutical Sciences and Research, Vol. 6, No. 8, pages 3,161-3, Adeline Siew, Tackling challenges in the development of fixed-dose combinations, Pharmaceutical Technology, Vol. 38, No Adeline Siew, Fixed-Dose Combinations, Pharmaceutical Technology, Vol. 39, No. 12, pages Amar Patel and Bruhalkumar Shah are senior formulation scientists, Deep Patel is a formulation scientist, Satish Shetty is director of formulation development, and Anthony Qu is vice president of scientific affairs at Halo Pharmaceuticals ( , services@halopharma.com).
Application of Quality by Design (QbD) in product development. James E. Polli September 16, 2015
Application of Quality by Design (QbD) in product development James E. Polli jpolli@rx.umaryland.edu September 16, 2015 Pharmaceutical Equivalence Same active ingredient(s) Same dosage form Same route
More informationAdaptDose, an innovative platform that reduces product development time and costs by 30% or more
WHITE PAPER January 2017 AdaptDose, an innovative platform that reduces product development time and costs by 30% or more Frontida BioPharm, Inc. Ron Connolly 01.01.2017 CONTENTS ABSTRACT INTRODUCTION
More informationADVANTAGES OF MULTIPARTICULATES (PELLETS):
INTRODUCTION: Multiparticulate Drug Delivery Systems (MDDS): The concept of multiple unit dosage form was initially introduced in the early 1950 s.these forms play a major role in the design of solid dosage
More informationCHALLENGES AND OPPORTUNITIES ON FORMULATION AND DEVELOPMENT OF FIXED DOSE COMBINATIONS: UNIGEL, A TECHNOLOGICAL PLATFORM
CHALLENGES AND OPPORTUNITIES ON FORMULATION AND DEVELOPMENT OF FIXED DOSE COMBINATIONS: UNIGEL, A TECHNOLOGICAL PLATFORM CLAUDIA SILVA, IVAN ROMERO, DIEGO MONTERROZA. PROCAPS S.A ABSTRACT This article
More informationImplementing Quality by Design Principles and Concepts to Drug Delivery and Formulation Development. S Betterman 15Apr2015
Implementing Quality by Design Principles and Concepts to Drug Delivery and Formulation Development S Betterman 15Apr2015 Agenda Background Implementation Strategy Infrastructure Building Project Application
More informationHow to Identify Critical Quality Attributes and Critical Process Parameters
How to Identify Critical Quality Attributes and Critical Process Parameters Jennifer Maguire, Ph.D. Daniel Peng, Ph.D. Office of Process and Facility (OPF) OPQ/CDER/FDA FDA/PQRI 2 nd Conference North Bethesda,
More informationMeeting Solid Dose Formulation Challenges
Streamlining (Fast Tracking) Solid Dosage Form Development Tony Carpanzano, B.S., R. Ph. Director, Research & Development Streamlining (Fast Tracking) Solid Dosage Form Development Meeting Solid Dose Formulation
More informationQuality by Design, Revolution or Evolution? Wim Oostra
Quality by Design, Revolution or Evolution? Wim Oostra 1993 1998 2007 2009 2013 And many more.. Content Introduction A bit of history Examples A New product Legacy product Today? The triggers The goal
More informationQuality by Design (QbD)
Evaluating the Critical Quality attributes & Critical Process Parameters-A Case Study-Tablets GMP International Workshop February 20/21, 2008 Mumbai, India Mukund Yelvigi Director, Therapeutic Area Management,
More informationRapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products
RapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products Kevin Kane, Scientific Director, BCP 7 th Annual Global Drug Delivery & Formulation Summit 28 th August
More informationQbD implementation in Generic Industry: Overview and Case-Study
QbD implementation in Generic Industry: Overview and Case-Study Inna Ben-Anat, QbD Strategy Leader, Teva Pharmaceuticals IFPAC JAN 2013 R&D Three Core Components of QbD and Generic Industry: How Do They
More informationOutline CLINICALLY RELEVANT SPECIFICATIONS. ISPE Process Validation Conference September 2017 Bethesda, MD
CLINICALLY RELEVANT SPECIFICATIONS Patrick J Marroum Ph.D. Senior Director and ACOS Senior Research Fellow Department of Clinical Pharmacology and Pharmacometrics Abbvie Pharmaceuticals Outline CMC variables
More informationReal-Time Prediction of Polymer-Coated Multiparticulate Dissolution using Process Analytical Technology
Real-Time Prediction of Polymer-Coated Multiparticulate Dissolution using Process Analytical Technology Authors: Piyush Patel A, Edward Godek B, Chris O Callaghan C, Dr. Ian Jones D A Colorcon, PA, USA
More informationBalancing the time, cost and risk of drug development. Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL
Balancing the time, cost and risk of drug development Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL Communicating vessels Risk Time Cost Communicating vessels
More informationProviding insight into pharmaceutical formulations
Providing insight into pharmaceutical formulations Dr Steve Ward-Smith Pharmaceutical Industry The average cost of developing a drug is reported to be approx $500 million, but up to 70% of new chemical
More informationUniversity of Sulaimani College of Pharmacy Dept. of Pharmaceutics 5 th stage Second Semester
University of Sulaimani College of Pharmacy Dept. of Pharmaceutics 5 th stage Second Semester 2/26/2018 Industrial Pharmacy II, Dr. rer. nat. Rebaz Ali 1 Outlines Powder flow Introduction Factor affecting
More informationin full-service contract pharmaceutical development and manufacturing
in full-service contract pharmaceutical development and manufacturing THE Norwich Advantage Norwich is a recognized leader in full service contract pharmaceutical development and manufacturing. As a single-source
More information2nd FDA/PQRI Conference on Advancing Product Quality
2nd FDA/PQRI Conference on Advancing Product Quality Generic Pharma Perspective on the Identification of Critical Quality Attributes and Critical Process Parameters Bruce D. Johnson, Ph.D. Vice President
More information7th Training School on Microencapsulation Strasbourg. Februar 2015 Textmasterformat in Mastervorlage eingeben
7th Training School on Microencapsulation Strasbourg Februar 2015 1 Dr. Anne Ettner, Glatt Pharmaceutical Services 2 Overview 1. Introduction 2. Fluid bed equipment 3. Basics of fluid bed Wurster technology
More informationApplied Process Understanding in Drug Product Development
Applied Process Understanding in Drug Product Development A combined pharmaceutical science, materials science and chemical process engineering approach 17 October, Heidelberg, Germany ir Sander van den
More informationContent PART I: ANDA Roadmap PART II: Understanding of CPPs & CQAs PART III: Scale-Up and Technology Transfer PART IV: Process Validation & Sampling 2
EMA, FDA- ANDA Readiness -OSD Generics Solution Post Formulation Development Horch Guo, May. 2016, Changzhou, China Hongxing.guo@yahoo.com Content PART I: ANDA Roadmap PART II: Understanding of CPPs &
More informationToxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development
Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development No. 1 of 10 1. regulates all the drugs products manufactured and sold in the USA. (A) EMEA (B) IND (C) FDA (D) NDA (E) OSHA
More informationBetter wet granulation: development, scale-up and manufacture
Better wet granulation: development, scale-up and manufacture By Tim Freeman, Freeman Technology Wet granulation is a common unit operation in the pharmaceutical industry yet accurate endpoint detection
More informationcoating Layering an API onto tablets using a perforated-drum coater: A case study ACG Pharma Technologies
As appeared in Tablets & Capsules April 201 coating www.tabletscapsules.com Layering an API onto tablets using a perforated-drum coater: A case study Vasant Shetty, Sameer Borate, Anuprita Landge, and
More informationConducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development
Conducting Successful pre-ind Meetings to Reach FDA Concurrence for Sound 505(b)(2) Development 2015 AAPS Annual Meeting and Exposition October 28, 2015 Kimberly Raines, Ph.D. Lead Pharmacologist Quality
More informationPharmaceutical Sciences
SRI International Biosciences From Idea to IND Research on Disease Mechanisms Drug Discovery Drug Metabolism, Pharmacokinetics, & Toxicology Services Pharmaceutical Sciences Preclinical Development Planning
More informationPAT in Action: A Lifecycle Approach to Applied Process Understanding to set meaningful process and product specifications October, Heidelberg, Germany
PAT in Action: A Lifecycle Approach to Applied Process Understanding to set meaningful process and product specifications October, Heidelberg, Germany ir Sander van den Ban, CEng The Unpredictability of
More informationGuidance for Industry
Guidance for Industry ANDAs: Blend Uniformity Analysis DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should
More informationIndustry Perspective on Lifecycle Management
Industry Perspective on Lifecycle Management and Post-Approval Building Changes the Best title here Focus on Quality by Design FDA/PQRI Conference on Evolving Product Quality Sep. 16-17, 2014 Michael Kimball
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL FIXED DOSE COMBINATION PRODUCTS (FDC Products) FOR HIV/AIDS, TUBERCULOSIS, and MALARIA This guideline is intended to provide recommendations to applicants wishing to submit applications
More informationA Comprehensive Review on Quality by Design (QbD) in Pharmaceuticals
Review Article Hardik Patel* 1, Shraddha Parmar 1, Bhavna Patel 1 1 Post Graduate Department of Pharmaceutical Sciences, Sardar Patel University, Vallabh Vidyanagar, Gujarat, India. *Corresponding author
More informationBiowaiver Approaches for Solid Oral Dosage Forms in New Drug Applications Poonam R. Delvadia, Ph.D. Division of Biopharmaceutics\ONDP\OPQ\CDER\FDA
Biowaiver Approaches for Solid Oral Dosage Forms in New Drug Applications Poonam R. Delvadia, Ph.D. Division of Biopharmaceutics\ONDP\OPQ\CDER\FDA PQRI BTC Webinar December 06, 2018 DISCLAIMER The presentation
More informationImpact factor: 3.958/ICV: 4.10 ISSN:
Impact factor: 3.958/ICV: 4.10 ISSN: 0976-7908 312 Pharma Science Monitor 9(2),Apr-Jun 2018 PHARMA SCIENCE MONITOR AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES Journal home page: http://www.pharmasm.com
More informationPharma & Food Solutions. ETHOCEL One of the Few Water-Insoluble Polymers Approved for Global Pharmaceutical Applications
Pharma & Food Solutions ETHOCEL One of the Few Water-Insoluble Polymers Approved for Global Pharmaceutical Applications ETHOCEL Premium Polymers are essentially tasteless, colorless, odorless, noncaloric
More informationWe make drugs smarter
We make drugs smarter Brookwood Pharmaceutical Services WE MAKE DRUGS SMARTER Using our 40 years of experience, our state of the art facilities and our IP protected technologies, we leverage existing capabilities
More informationRegulatory Assessment
Implementation of ICH Q8, Q9, Q10 Regulatory Assessment International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Presentation Overview Goal
More informationOral Dosage Formulation Development
Oral Dosage Formulation Development Achieving faster formulation of solid oral dosage forms for FIH supplies Dr. Colin Lorimer - published April 29, 2011 The pharmaceutical industry is increasingly looking
More informationProcess Drift: When Do We Detect it? Richard L. Friedman Director, DMPQ CDER/Office of Compliance PQRI Process Drift Workshop December 1, 2010
Process Drift: When Do We Detect it? Richard L. Friedman Director, DMPQ CDER/Office of Compliance PQRI Process Drift Workshop December 1, 2010 Overview Goal of Manufacturing Central Question: Why is process
More informationGuidance for Industry
Guidance for Industry Handling and Retention of BA and BE Testing Samples U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) May 2004
More informationEvonik Birmingham Laboratories
Evonik Birmingham Laboratories An integrated CDMO for advanced parenterals with a portfolio of delivery technologies, formulation development services and GMP manufacturing Evonik Birmingham Laboratories
More informationContinuous Manufacturing
Continuous Manufacturing Continuous ing in the Industry Continuous processing has been adopted by the majority of process industries for the manufacturing of fluids (i.e. liquids and gasses) and solids
More informationQuality by Design and Expertise: Accelerating time to market of complex oral solid dosage forms
CPhI Worldwide 2017 October 24 th -v 26 th, 2017 Frankfurt Quality by Design and Expertise: Accelerating time to market of complex oral solid dosage forms Lucile KOWALSKI - NPI Project Manager Guy VERGNAULT
More informationFormulation Development & CTM Manufacturing Services
Formulation Development & CTM Manufacturing Services VxP Pharma Purdue Research Park 5225 Exploration Drive Indianapolis, IN 46241 Tel: 317.759.2299 Fax: 317.713.2950 VxP Pharmaprovides an extensive range
More informationCombination Products Raise Manufacturing Challenges
WASHINGTON REPORT Combination Products Raise Manufacturing Challenges Jill Wechsler Jill Wechsler is Pharmaceutical Technology s Washington editor, 7715 Rocton Ave., Chevy Chase, MD 20815, tel. 301.656.4634,
More informationInstitute of Pharmaceutical Technology and Biopharmacy University of Pécs szeptember 22. 1
Institute of Pharmaceutical Technology and Biopharmacy University of Pécs 2017. szeptember 22. 1 Pre-discovery Goal: Understand the disease and choose a target molecule. How: Scientists in pharmaceutical
More informationCHAPTER INTRODUCTION 1.1 ORAL DRUG DELIVERY: SCOPE AND ADVANTAGES
1.0 INTRODUCTION 1.1 ORAL DRUG DELIVERY: SCOPE AND ADVANTAGES Oral ingestion is the preferred route for administration of therapeutic agents, providing a convenient method of effectively achieving both
More informationWHITE PAPER: Amorphous Solid Dispersions-One approach to improving Bioavailability
2017 WHITE PAPER: Amorphous Solid Dispersions-One approach to improving Bioavailability Eric C Buxton Clinical Associate Professor University of Wisconsin Madison School of Pharmacy, Division of Pharmacy
More informationHermes_highlights_need_for_better_formats_OTCBulletin_ pdf. Published July Accessed July 10, 2016.
Introduction An online survey conducted in the United States found that 50% of surveyed American adults (N = 1002) reported difficulty swallowing tablets and capsules. 1 These numbers are even higher in
More informationThe science of transforming an Active Pharmaceutical Ingredient (API) into a Drug Product (DP) in a specific dosage form.
The science of transforming an Active Pharmaceutical Ingredient (API) into a Drug Product (DP) in a specific dosage form. Three major needs that the formulation into a specific dosage form directly address
More informationICH Q9 An Industry Perspective: Ensuring Quality to Patients in a Risk-Based Regulatory Environment
ICH Q9 An Industry Perspective: Ensuring Quality to Patients in a Risk-Based Regulatory Environment Thomas Schultz, Ph.D. Director, Regulatory Sciences Johnson & Johnson September 12, 2007 Presentation
More informationFormulation Development of New Chemical Entities (NCEs) Dr. Mariella Artusi Pharmaceutical Development Dept. Monza
Formulation Development of New Chemical Entities (NCEs) Dr. Mariella Artusi Pharmaceutical Development Dept. Monza HorizonChem 2018, March, 6th 2018 1 Content Rottapharm Biotech : Company Overview Formulation
More informationCGMP Requirements for Investigational Products
PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health
More informationQuality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review
Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review Presented by Erika E. Englund, Ph.D. Slides courtesy of Dorota Matecka, Ph.D. Office of Pharmaceutical
More informationHow to Avoid Common Deficiencies in INDs and NDAs. Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER
How to Avoid Common Deficiencies in INDs and NDAs Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER 1 Structure of FDA Office of Commissioner Chief Scientist FOODS Medical Products & Tobacco
More informationPHARMACEUTICAL MANUFACTURING
PHARMACEUTICAL MANUFACTURING WHAT IS PHARMACEUTICAL MANUFACTURING IT IS THE PROCESS OF INDUSTRIAL SCALE SYNTHESIS OF PHARMACEUTICAL DRUG BY PHARMACEUTICAL COMPANIES. THE PROCESS CAN BE BROKEN DOWN INTO
More informationIdentification of CPPs based on CQAs & Mechanistic Process & Product Understanding: A Case Study
Identification of CPPs based on CQAs & Mechanistic Process & Product Understanding: A Case Study Ajit S. Narang, Ph.D. Bristol-Myers Squibb, Co. 2 nd FDA/PQRI Conference on Advancing Product Quality Bethesda,
More informationThe Emerging Technology Program: FDA s Perspective
The Emerging Technology Program: FDA s Perspective Mohan Sapru, M.S., Ph.D. Member Emerging Technology Team (ETT) CMC Lead Application Technical Lead Office of New Drug Products Office of Pharmaceutical
More informationDevelopment of paediatric formulations - points to consider
Development of paediatric formulations - points to consider Workshop on Paediatric Formulations II London, 8 November 2011 Presented by: Ann Marie Kaukonen Scientific Administrator, Paediatric Medicines,
More informationAN INTRODUCTION TO SPHERONIZATION (MARUMERIZATION * )
A TECHNICAL NOTE LABORATORY / PRODUCTION CALEVA (MARUMERIZATION * ) A Brief Non-Technical General Guide interchangeably. *Spheronization and marumerization, different names for the same thing. The two
More informationAt LATITUDE, we only do one thing, and we do it very well.
Formulation Experts for Insoluble Compounds At LATITUDE, we only do one thing, and we do it very well. LATITUDE Pharmaceuticals Inc. has been tackling the most difficult drug formulation challenges for
More informationINTER CHANGEABILITY and EQUIVALENCE. Where we are and what we still have to determine!
INTER CHANGEABILITY and EQUIVALENCE Where we are and what we still have to determine! Acknowledgement Joint presentation UNICEF/MSF/ICRC Cecile Mace Jean Michel Caudron Birgit Schmauser What do we mean
More informationApproval Review of Generic Drugs. Office of Generic/OTC Drugs, PMDA Kazuyuki SAITO, Ph.D.
Approval Review of Generic Drugs Office of Generic/OTC Drugs, PMDA Kazuyuki SAITO, Ph.D. Outline of Presentation Introduction Approval Review of Generic Drugs Equivalency review Conformity audit Conclusion
More informationADVANCES IN PHARMACEUTICAL INDUSTRY FOR WELLNESS AND SUSTAINABLE HEALTH
ADVANCES IN PHARMACEUTICAL INDUSTRY FOR WELLNESS AND SUSTAINABLE HEALTH Faculty of Pharmaceutical Sciences Chulalongkorn University Industrial pharmacy is a discipline which includes manufacturing, development,
More informationControl Strategy. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 Control Strategy International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Introduction Structure of this session
More informationMETHOCEL. TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow
METHOCEL Cellulose Ethers A product that can do it all TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow The possibilities are endless Pharmaceutical companies are continuously
More informationOSDrC OptiDose : A Revolution in Drug Formulation Technology
Review Article OSDrC OptiDose : A Revolution in Drug Formulation Technology Sayantany Chandra*, Sayantan Sadhukhan, Sabyasachi Maiti, Somasree Ray Department of Pharmaceutics, Gupta College of Technological
More informationInternational Journal of Pharma and Bio Sciences IMPACT OF SOFT GELATIN CAPSULES FORMULATIONS FOR ORAL ADMINISTRATION ABSTRACT
Review Article Pharmaceutics International Journal of Pharma and Bio Sciences ISSN 0975-6299 IMPACT OF SOFT GELATIN CAPSULES FORMULATIONS FOR ORAL ADMINISTRATION BODAVULA.SAMBA SIVA RAO Khammam college
More informationFIP STATEMENT OF POLICY Pharmacist's authority in pharmaceutical product selection: therapeutic interchange and substitution
Pharmacist's authority in pharmaceutical product selection: therapeutic interchange and substitution Purpose: The purpose of this document is to provide a set of recommendations on therapeutic interchange
More informationQbD (Quality by Design) Has industry benefited from this? WHITE PAPER.
WHITE PAPER www.makrocare.com/consulting There are many facets to engineering for a healthier world. It is important to understand what surrounds us today and look into what we believe will surround us
More informationAdvances in powderdosing
Advances in powderdosing technology A new technology offers a step-change in the way that early clinical trial supplies can be formulated resulting in real savings in development times and costs. Simon
More informationFormulation Development
Quality by Design and Formulation Development WF Busch Senior Application Development Specialist Dow Chemical Company IPEC Americas, Quality by Design Committee 5 May 2010 Disclaimer The views and opinions
More informationa piece of cake? Solid dosage forms are the most popular
Multilayer tablets: a piece of cake? Solid dosage forms are the most popular method of drug delivery and no doubt many of you spend your days toiling over troublesome tablets! Although tablets are widely
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:
More informationSolid dosage forms are a wellestablished,
Solid dosage forms are a wellestablished, widely-used delivery method, yet they are also an area of innovation that can slash drug development times and costs while improving patient outcomes. The tablet
More informationFuture of Question-based Review and Regulatory Submissions
Future of Question-based Review and Regulatory Submissions Robert Iser Associate Director for Policy Development (Acting) Office of Pharmaceutical Science / CDER / FDA FDA/PQRI Conference on Evolving Product
More informationManufacturing Considerations for Liposomal Drug Products. Nanotechnology Workshop January 2014
Manufacturing Considerations for Liposomal Drug Products Nanotechnology Workshop January 2014 Applications of Nano-Scale Drug Delivery Systems Wide range of carrier types Liposomes Solid core nanoparticles
More informationPHARMACEUTICAL PRINCIPLES OF SOLID DOSAGE FORMS
PHARMACEUTICAL PRINCIPLES OF SOLID DOSAGE FORMS J. T. Carstensen, Ph.D. Professor of Pharmacy University of Wisconsin Madison, Wisconsin TECHNOMIC ^PUBLISHING CO.. INC J 1.ANCASTER BASET, TABLE OF CONTENTS
More informationGUIDANCE DOCUMENT Use of a Foreign-sourced Reference Product as a Canadian Reference Product
GUIDANCE DOCUMENT Use of a Foreign-sourced Reference Product as a Canadian Reference Product Published by authority of the Minister of Health Date Adopted 2017/11/24 Effective Date 2017/11/24 Health Products
More informationWHOPAR. SCIENTIFIC DISCUSSION
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationBest Practices In Pharmaceutical Formulation Development
1 Best Practices In Pharmaceutical Formulation Development 18-05-2018 2 Who are we? Your partner in achieving excellence Sidvim provides experience based, specialized consultancy services across all functional
More informationFirst UNGAP meeting Food-Drug Interactions Regulatory Aspects
First UNGAP meeting Food-Drug Interactions Regulatory Aspects Leuven, 09 March 2018 Dr. Henrike Potthast HPt COST meeting, Leuven, BE 09 March 2018 Page 1 Disclaimer The presentation reflects the personal
More informationUSP s Perspective on Drug Product Performance Test
USP s Perspective on Drug Product Performance Test Course Overview 1. The concept of in vitro dissolution Definition and application 2. Compendial dissolution/ drug release testing 3. Method development
More informationAccelerating development of enabled formulations for poorly soluble drugs
Accelerating development of enabled formulations for poorly soluble drugs John McDermott, Executive Director, Drug Product Optimisation Efficacy issues due to inadequate gastrointestinal (GI) absorption
More informationPelletization Techniques: A Review
ABSTRACT: Pelletization is an agglomeration process that converts fine powders or granules of bulk drugs and excipients into small, free flowing, spherical or semi-spherical units, referred to as pellets.
More informationClinically Relevant Specifications (CRS): A Regulatory Perspective
Clinically Relevant Specifications (CRS): A Regulatory Perspective Richard (Rik) Lostritto, Ph.D. Acting Deputy Director for Science & Policy and Acting Biopharmaceutics Lead, Office of New Drug Quality
More informationCHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE
CHALLENGES & OPPORTUNITIES OF ICHQ8 (PHARMACEUTICAL DEVELOPMENT) AN INDUSTRY PERSPECTIVE Paul Stott, PhD Head of US Product Development AstraZeneca ICH Quality Guidelines Workshop BioKorea 2007 Sept 13-14
More informationA Framework and Case Study for Implementing the New Process Validation Guidance
A Framework and Case Study for Implementing the New Process Validation Guidance Presented By Bikash Chatterjee President and Chief Technology Officer Pharmatech Associates Agenda Introduction Comparing
More informationReview Article Review on Quality by Designing for Metered Dose Inhaler Product Development Santosh R. Thorat * 1, Sarika M.
Scholars Academic Journal of Pharmacy (SAJP) Sch. Acad. J. Pharm., 2015; 4(6): 324-330 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources) www.saspublisher.com
More informationSakura Bloom Tablets P2 Mock
Sakura Bloom Tablets P2 Mock Mock P2 English version Sakura Bloom Tablets Disclaimer This mock provides an example of the contents to be included in CTD 2.3.P.2 Pharmaceutical Development section for a
More informationPublic Assessment Report. Scientific discussion. Furosemid Orifarm 40 mg tablets. (Furosemide) DK/H/2430/001/DC. 1 December 2015
Public Assessment Report Scientific discussion Furosemid Orifarm 40 mg tablets (Furosemide) DK/H/2430/001/DC 1 December 2015 This module reflects the scientific discussion for the approval of Furosemid
More informationClinical Trials A Closer Look
The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription and over-the counter) Food Medical devices Animal feed and drugs Cosmetics
More informationGuidance for Industry
Guidance for Industry Submission of Abbreviated Reports and Synopses in Support of Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationGDUFA II Pre-ANDA Program Meetings for Complex Products
GDUFA II Pre-ANDA Program Meetings for Complex Products Robert Lionberger Director, Office of Research and Standards Office of Generic Drugs AAM Fall Technical Meeting November 7, 2017 GDUFA II Pre-ANDA
More informationAbstract. Technical Aspects. Applying GastroPlus for Extensions of Biowaivers for BCS Class II Compounds 2
Abstract GastroPlus is a mechanistically based simulation software package that predicts absorption, pharmacokinetics, and pharmacodynamics in humans and animals. GastroPlus modeling and simulation has
More informationLearning from the Application of Real-Time Analytics for Process Understanding, Control and Real-Time Release Testing
Learning from the Application of Real-Time Analytics for Process Understanding, Control and Real-Time Release Testing Ruben Lozano, Douglas Both and Ambarish Singh Bristol-Myers Squibb Biopharmaceutics
More informationINSIGHT-DRIVEN FORMULATIONS DEVELOPMENT
INSIGHT-DRIVEN FORMULATIONS DEVELOPMENT HOW AN INTEGRATED DEVELOPMENT PLATFORM CAN PROVIDE END-TO-END VISIBILITY ACROSS PRE-FORMULATIONS AND FORMULATIONS DEVELOPMENT 1 A considerable amount and variety
More informationCATEGORY Advertising. CATEGORY Biopharmaceutics. CATEGORY Biosimilarity
Guidance Agenda: New & Revised Draft Guidances CDER is Planning to Publish During Calendar Year 2015 (See the Good Guidance Practices (GGPs) regulation on this Web page or 21 CFR 10.115 for details about
More informationBasic Principles for Conducting Phase I Trials in the Japanese Population Prior to Global Clinical Trials
Administrative Notice October 27, 2014 To: Prefectural Health Department (Bureau) Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Basic
More informationWHO DRAFT PHARMACEUTICAL DEVELOPMENT FOR MULTISOURCE (GENERIC) PHARMACEUTICAL PRODUCTS
23 April 2008 Quality Assurance Programme Quality Assurance and Safety: Medicines (QSM) Department of Medicines Policy and Standards (PSM) World Health Organization CH-1211 Geneva 27 Switzerland WHO DRAFT
More informationIndustry Perspective on Manufacturing in Early Development
Industry Perspective on Manufacturing in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Eric Schmitt AbbVie IQ Drug Product Manufacturing Working Group August 2012 issue of Pharmaceutical
More information